[CAS NO. 98-92-0] Nicotinamide

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [98-92-0]

Catalog

HY-B0150

Brand

MCE

CAS

98-92-0

DESCRIPTION [98-92-0]

Overview

MDL	MFCD00006395
Molecular Weight	122.12
Molecular Formula	C6H6N2O
SMILES	O=C(C1=CC=CN=C1)N

For research use only. We do not sell to patients.

26 Publications Citing Use of MCE

Summary

Nicotinamide is a form of vitamin B3 or niacin that inhibits sirtuin 2 ( SIRT2 ) activity in vitro , with an EC ₅₀ of 2 μM. Nicotinamide inhibits up to 90% melanoma cell number and increases cellular NAD ₊ , ATP, ROS levels. Nicotinamide inhibts tumor growth in vivo and improves survival of melanoma-bearing mice, which can be used for the research of skin cancers such as melanoma ^[1] .

IC50 & Target

PARP-1

Human Endogenous Metabolite

SIRT2

2 μM (EC ₅₀ )

In Vitro

Nicotinamide (0-50 mM, 24/48 h ) reduces cell number in a time-dependent and dose-dependent manner in A375 and SK-MEL-28 cells ^[1] .
Nicotinamide (10-50 mM, 24 h ) makes A375 cells undergo accumulation in G1 phase, reduction in S phase, and increase inthe sub-G1 (apoptosis) phase ^[1] .
Nicotinamide (1-50 mM, 6 h ) increases NAD ₊ , ATP and ROS levels in A375 and SK-MEL-28 cells ^[1] .
Nicotinamide (0.01-20 mM, 1 h) inhibits purified SIRT2 enzymatic activity in vitro with an EC ₅₀ of 2 μM ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	A375, SK-MEL-28, mouse B16-F10 cell
Concentration:	0, 1, 20, 50 mM
Incubation Time:
Result:	24 h, 48 h

Cell Cycle Analysis ^[1]

Cell Line:	A375, SK-MEL-28
Concentration:	10, 20, 50 mM
Incubation Time:	24 h
Result:	Arrested A375 cells in G1 phase.

In Vivo

Nicotinamide (Intraperitoneal injection, 1500 and 1800 mg/Kg, 5 days per week) inhibits tumor growth in murine metastatic melanoma model ^[1] .
Nicotinamide (Intraperitoneal injection, 1800 mg/Kg, once a day, murine metastatic melanoma model) affects IFN-γ (a key mediator of cell-mediated anti-tumor immunity), increases the plasma levels of eotaxin and IL-5, reduces the plasma levels of IL-3, IL-12, RANTES and IL-10 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (subcutaneous injected with B16-F10 cells) ^[1]
Dosage:	1000, 1500, 1800 mg/Kg.
Administration:	Intraperitoneal injection, 5 days per week (followed by 2-day rest) or once a day.
Result:	Inhibited tumor growth at 1500 and 1800 mg/Kg, and had no effect on the body weight. Increased the frequency of IFN-γ producing cells and modulated the protein levels of cytokines and chemokines in the plasma of tumor-bearing mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04910061	Seneque SA\|Dicentra Inc.\|LGD	Healthy Volunteers	August 5, 2021	Not Applicable
NCT05258474	University Hospital Schleswig-Holstein	Safety Issues\|Pharmacokinetic	December 4, 2020	Phase 1
NCT05194397	Children´s Hospital of Philadelphia\|National Institutes of Health (NIH)\|City of Hope Medical Center\|St. Jude Children´s Research Hospital\|National Cancer Institute (NCI)\|University of Pennsylvania	Acute Lymphoblastic Leukemia in Remission\|Cancer Survivors	November 18, 2022	Phase 2
NCT04112641	Donna Hammond, PhD\|University of Iowa	Chemotherapy-induced Peripheral Neuropathy	February 19, 2020	Phase 2
NCT03754842	University of Aarhus\|University of Copenhagen	Muscle Injury	February 12, 2019	Not Applicable
NCT05589766	Haukeland University Hospital	Parkinson Disease	November 15, 2022	Not Applicable
NCT03392623	Universidad Autonoma de San Luis Potosí	Melasma	January 1, 2015	Early Phase 1
NCT02721537	Mayo Clinic\|University of Minnesota\|Thorne Research Inc.	Concussion, Mild	September 2016	Not Applicable
NCT02416739	Il Yeong Park, Ph.D.\|Chungbuk National University	Non-Small-Cell Lung Carcinoma	March 2015	Phase 2\|Phase 3
NCT04862338	Seneque SA\|CEN Biotech\|LGD	Healthy Volunteers	April 26, 2021	Not Applicable
NCT04903210	First Affiliated Hospital, Sun Yat-Sen University	Hypertension	June 1, 2021	Phase 4
NCT04218500	Indonesia University	Contact Dermatitis of Hands	September 3, 2019	Not Applicable
NCT04823260	Abinopharm, Inc\|ProRelix Services LLP	Aging	May 25, 2021	Not Applicable
NCT01381354	University of Iowa\|Direct MS Canada\|DJO Incorporated\|Pinnaclife Inc.\|TZ Press, LLC	Multiple Sclerosis	October 2010	Phase 1
NCT00140166	Beersheva Mental Health Center\|Supported by a Hilton Family Foundation grant to\|International Schizophrenia Foundation	Acute Schizophrenia	July 2005	Phase 4
NCT04905446	AdventHealth Translational Research Institute	Skeletal Muscle	September 10, 2021	Not Applicable
NCT03579693	University of Washington\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Chronic Kidney Disease\|Sarcopenia\|Frailty	November 14, 2018	Phase 2
NCT03260166	Second Xiangya Hospital of Central South University\|National Natural Science Foundation of China\|Hunan Provincial Natural Science Foundation of China\|National Key Clinical Specialty Construction Project of China	Cutaneous Lupus Erythematosus\|Systemic Lupus Erythematosus Rash	August 31, 2017	Phase 2
NCT03061474	University of California, Irvine	Alzheimer´s Disease\|Mild Cognitive Impairment	July 12, 2017	Phase 2
NCT01542138	Universidad Autonoma de San Luis Potosí\|Hospital Central Dr. Ignacio Morones Prieto	Hyperpigmentation	July 2011	Phase 4
NCT05617508	Haukeland University Hospital\|Haraldsplass Deaconess Hospital	Alzheimer Disease\|Dementia	November 2022	Not Applicable
NCT01011699	Centre Hospitalier Universitaire, Amiens	Chronic Renal Failure\|Hemodialysis	January 2010	Phase 3
NCT03151707	Mclean Hospital	Healthy	October 1, 2017	Phase 4
NCT03423342	University of Washington\|National Heart, Lung, and Blood Institute (NHLBI)	Heart Failure, Systolic	May 19, 2016	Phase 1\|Phase 2
NCT05362188	Al-Azhar University	Discoid Lupus Erythematosus	March 1, 2022	Early Phase 1
NCT05561738	University of Pittsburgh\|Crohn´s and Colitis Foundation	Ulcerative Colitis	January 1, 2023	Not Applicable
NCT05546567	Haukeland University Hospital	Safety Issues	September 28, 2022	Not Applicable
NCT05017428	University of California, Davis	Postprandial Inflammation	April 8, 2021	Not Applicable
NCT05344404	Haukeland University Hospital	Parkinson Disease	April 29, 2022	Not Applicable
NCT00605930	University of Louisville	Progressive Supranuclear Palsy	April 2004	Not Applicable
NCT04589546	Centre Hospitalier Universitaire, Amiens\|Centre Hospitalier de Dieppe\|Centre Hospitalier d´Abbeville\|Centre Hospitalier de Laon\|University Hospital, Caen\|Centre Hospitalier de Cherbourg\|University Hospital, Rouen\|Centre Hospitalier de Roubaix\|Centre Hospitalier de Bethune\|Hôpital Saint Philibert, Lomme\|Tourcoing Hospital\|Centre Hospitalier de Valenciennes\|Centre Hospitalier Arras\|Centre Hospitalier de Lens\|Centre Hospitalier de Calais	Acute Kidney Injury\|Septic Shock\|Nicotinamide\|Mortality	October 1, 2020	Phase 3
NCT04910230	Qiang Hu\|Shenyang Northern Hospital	Covid19\|Lymphopenia	March 1, 2020	Not Applicable
NCT01368887	DermiPsor, Ltd.	Psoriasis	April 2013	Phase 2
NCT04990869	University of Copenhagen\|Bispebjerg Hospital\|Elysium Health	COPD	July 1, 2021	Not Applicable
NCT03565328	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Heart Failure	September 27, 2018	Phase 2
NCT05243290	Roskamp Institute Inc.\|United States Department of Defense\|Nova Southeastern University	Gulf War Illness	April 13, 2022	Not Applicable
NCT00893724	Mid-Atlantic Retina Consultations, Inc.\|West Virginia University	Neovascular Age-related Macular Degeneration\|Diabetic Macular Edema	June 2009	Not Applicable
NCT04342975	Mayo Clinic\|Elysium Health	AKI	December 1, 2020	Phase 2
NCT00316472	Washington University School of Medicine	Hyperphosphatemia	April 2006	Phase 1
NCT04528004	University of Washington\|National Heart, Lung, and Blood Institute (NHLBI)	Heart Failure, Systolic\|Heart Failure NYHA Class IV\|Metabolic Disturbance	September 26, 2020	Early Phase 1
NCT05483465	University of Oklahoma\|University of Pennsylvania\|Oklahoma Medical Research Foundation\|Elysium Health	Aging	December 1, 2022	Phase 4
NCT02303483	Aarhus University Hospital\|University of Copenhagen	Obese	January 4, 2016	Not Applicable
NCT03769285	Women´s College Hospital\|Canadian Institutes of Health Research (CIHR)\|The Kidney Foundation of Canada\|NOW Foods\|Natural Life Nutrition	Non-melanoma Skin Cancer\|Carcinoma, Squamous Cell\|Carcinoma, Basal Cell	December 3, 2018	Phase 2
NCT04725253	University of Chile\|Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT (Chile).	Delirium Confusional State	January 21, 2021	Not Applicable
NCT03432871	Cambridge University Hospitals NHS Foundation Trust\|University of Cambridge\|MRC Mitochondrial Biology Unit	Mitochondrial Diseases\|Mitochondrial Myopathies\|Progressive External Ophthalmoplegia\|Progressive Ophthalmoplegia\|Progressive; Ophthalmoplegia, External\|Mitochondria DNA Deletion\|MELAS\|Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes\|Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)	December 8, 2017	Not Applicable
NCT03136705	Northwestern University	Healthy	February 3, 2016	Phase 1
NCT03761511	RWTH Aachen University\|Assistance Publique - Hôpitaux de Paris	Friedreich Ataxia	April 2023	Phase 2
NCT05175768	Vedic Lifesciences Pvt. Ltd.	COVID-19 Infection	December 27, 2021	Not Applicable
NCT04040959	University of Colorado, Denver\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Vascular Diseases\|Kidney Disease\|Blood Pressure\|Oxidative Stress	November 19, 2019	Phase 2
NCT04750616	Kaiser Permanente\|National Heart, Lung, and Blood Institute (NHLBI)\|Beth Israel Deaconess Medical Center\|Cedars-Sinai Medical Center	Ischemia Reperfusion Injury\|Myocardial Injury\|Acute Kidney Injury	September 13, 2021	Phase 2
NCT05275738	Umeå University\|Centre for Eye Research Australia\|Karolinska Institutet\|Singapore National Eye Centre\|Duke-NUS Graduate Medical School\|University of Melbourne\|University of Adelaide\|Lund University\|Linkoeping University\|Göteborg University	Glaucoma	May 18, 2022	Not Applicable
NCT03419364	University of North Carolina, Chapel Hill\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Pre-Eclampsia\|Pregnancy Related	November 1, 2017	Phase 2
NCT03727646	University of Washington\|American Heart Association	Heart Failure?Congestive\|Heart Failure New York Heart Association Class IV\|Mitochondrial Alteration	September 26, 2018	Early Phase 1
NCT04332341	Case Comprehensive Cancer Center	Allogeneic Hematopoietic Cell Transplantation	May 19, 2020	Early Phase 1
NCT04843553	Rhode Island Hospital	Actinic Keratoses	October 14, 2016	Early Phase 1
NCT03850886	Ain Shams University	Non Alcoholic Fatty Liver Disease	January 15, 2019	Phase 2
NCT04430517	Mclean Hospital\|National Institute on Aging (NIA)	Mild Cognitive Impairment\|Mild Alzheimer Disease	March 2, 2022	Early Phase 1
NCT04055818	EpiDestiny, Inc.\|National Institutes of Health (NIH)\|National Heart, Lung, and Blood Institute (NHLBI)	Sickle Cell Disease	January 24, 2020	Phase 1
NCT04913805	University of Pennsylvania	Heart Failure With Preserved Ejection Fraction	October 11, 2021	Phase 2
NCT03808961	VA Office of Research and Development	Parkinson´s Disease	January 1, 2020	Not Applicable
NCT04751604	University Hospital Schleswig-Holstein	COVID-19	February 1, 2021	Not Applicable
NCT04112043	University of Florida\|National Institute on Aging (NIA)	Hypertension	July 28, 2020	Phase 1
NCT02942888	The University of Texas Health Science Center at San Antonio\|University of Texas\|South Texas Veterans Health Care System	Mild Cognitive Impairment\|NAD	November 30, 2017	Not Applicable
NCT03568968	Haukeland University Hospital	Parkinson Disease	May 15, 2020	Not Applicable
NCT03816020	Haukeland University Hospital	Parkinson Disease\|Neurodegenerative Diseases	March 9, 2019	Not Applicable
NCT01763424	Isfahan University of Medical Sciences	Psoriasis	July 2011	Phase 2\|Phase 3
NCT02258074	The Cleveland Clinic\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Chronic Kidney Disease	March 2015	Phase 2
NCT03019666	Masonic Cancer Center, University of Minnesota	Multiple Myeloma\|Non-Hodgkin Lymphoma\|Diffuse Large B Cell Lymphoma\|Mantle-Cell Lymphoma\|Follicular Lymphoma\|Indolent B Cell Lymphoma\|Primary Mediastinal Lymphoma\|Lymphoplasmacytic Lymphoma	October 18, 2017	Phase 1
NCT03974685	RDO Pharm.\|Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd.\|MedAlly Solutions Co., Ltd.	Healthy	December 12, 2018	Phase 1
NCT04110028	Oslo University Hospital\|ChromaDex, Inc.	Inflammation\|Acute Illness	October 1, 2019	Phase 1\|Phase 2
NCT03268902	Haydom Lutheran Hospital\|University of Virginia\|Bill and Melinda Gates Foundation	Malnutrition\|Stunting\|Cognitive Development\|Enteric Pathogens	September 5, 2017	Phase 2\|Phase 3
NCT03501433	Iowa State University	Aging\|Lipemia	February 1, 2018	Not Applicable
NCT01200784	Medice Arzneimittel Pütter GmbH & Co KG	Chronic Kidney Disease\|Hemodialysis\|Hyperphosphatemia	August 2010	Phase 2
NCT05517122	Nestlé	Healthy	June 27, 2022	Not Applicable
NCT04691986	VA Office of Research and Development\|University at Buffalo	Sarcopenia\|Nicotinamide Adenine Dinucleotide Concentration\|Muscle Quality and NAD&addition; Content	January 15, 2023	Not Applicable
NCT02213094	University of North Carolina, Chapel Hill\|North Carolina Translational and Clinical Sciences Institute	Pregnancy Induced Hypertension\|Superimposed Preeclampsia\|Hypertension	January 1, 2014	Phase 1
NCT01589809	Imperial College London	Neurodegenerative Disorders	June 2012	Phase 2
NCT02558595	University of Kansas Medical Center\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Polycystic Kidney Disease	September 22, 2015	Phase 2
NCT04012177	Vital Pakistan Trust\|Aga Khan University	Undernutrition	July 22, 2019	Not Applicable
NCT05530707	Farmoquimica S.A.\|Medcin Instituto da Pele	Atopic Dermatitis	September 5, 2022	Not Applicable
NCT03789175	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Cancer\|Skin Fibroblasts\|Muscle Weakness	March 25, 2019	Phase 1\|Phase 2
NCT01085981	East Suburban Ob Gyn	Female Sexual Dysfunction	April 2010	Not Applicable
NCT03821623	Douglas Seals\|University of Colorado, Boulder	Hypertension\|Aging	May 10, 2019	Phase 2
NCT04818216	The University of Texas Health Science Center at San Antonio\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	SARS-CoV-2 Infection\|Acute Kidney Injury	June 11, 2021	Phase 2
NCT03912220	Johns Hopkins University\|Adelson Medical Research Foundation	Small Fiber Neuropathy	September 1, 2020	Phase 2
NCT02140814	Alan Yu, MB, BChir\|University of Kansas Medical Center	Polycystic Kidney Disease	May 2014	Phase 2
NCT02689882	University of Washington\|National Heart, Lung, and Blood Institute (NHLBI)	Metabolic Disturbance	November 2015	Phase 1
NCT05513807	Assistance Publique - Hôpitaux de Paris\|Institut National de la Santé Et de la Recherche Médicale, France\|Centre National de la Recherche Scientifique, France	Delayed Graft Function	November 2022	Phase 3
NCT00508885	Washington University School of Medicine	Hyperphosphatemia	October 2006	Phase 1\|Phase 2
NCT04192136	Children´s Hospital of Philadelphia\|National Heart, Lung, and Blood Institute (NHLBI)	Friedreich Ataxia 1	September 3, 2020	Not Applicable
NCT05590468	Eduardo N. Chini\|Mayo Clinic	Mitochondrial Myopathy	November 2022	Phase 2
NCT04844528	University of Utah	Chronic Lymphocytic Leukemia	August 5, 2021	Phase 2
NCT03743636	Northwestern University\|American Heart Association	Peripheral Artery Disease	October 1, 2018	Phase 3
NCT03818802	Mayo Clinic	Healthy Elderly Volunteers	September 16, 2019	Not Applicable
NCT02950441	University of Birmingham	Aging	June 2016	Phase 2
NCT02300740	Aarhus University Hospital\|University of Copenhagen	Healthy Participants	December 2014	Early Phase 1
NCT05593939	University of Copenhagen\|Elysium Health	Aging	May 1, 2022	Phase 2
NCT02812238	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Atherosclerosis\|Diabetes\|Coronary Artery Disease	June 23, 2016	Not Applicable
NCT05500170	State University of New York at Buffalo	Cognitive Impairment\|Sleep Quality	December 30, 2022	Not Applicable
NCT04407390	University of Copenhagen\|Bispebjerg Hospital\|Elysium Health	COVID	June 1, 2020	Phase 2
NCT04670081	Central Institute of Mental Health, Mannheim\|Charite University, Berlin, Germany\|MIND Foundation gGmbH\|German Federal Ministry of Education and Research\|Usona Institute	Treatment-resistant Depression	June 10, 2021	Phase 2
NCT04870866	University Hospital, Akershus\|The Bergesen Foundation\|South-Eastern Norway Regional Health Authority\|Sykehuset Innlandet HF\|Oslo University Hospital\|St. Olavs Hospital\|Haukeland University Hospital\|University Hospital of North Norway\|University of Bergen	Ataxia Telangiectasia	June 5, 2019	Phase 2
NCT00033436	Mount Vernon Cancer Centre at Mount Vernon Hospital\|National Cancer Institute (NCI)	Bladder Cancer	October 2000	Phase 3
NCT00580931	University of California, Irvine\|Alzheimer´s Association	Alzheimer´s Disease	January 2008	Phase 1\|Phase 2
NCT04664361	Seneque SA\|CEN Nutriment\|Centre d´Expertise de la Performance\|LGD	Physical Activity\|Muscle Recovery	March 9, 2021	Not Applicable
NCT00691210	Columbia University\|Merck Sharp & Dohme LLC	Hodgkin´s Disease\|Non-Hodgkin´s Lymphoma	June 2008	Phase 1
NCT02758990	Verifomics LLC	Obesity\|Rhinitis\|Rhinitis, Allergic\|Respiratory Sounds\|Dyspnea\|Headache\|Migraine Disorders\|Arthritis\|Arthralgia\|Anxiety\|Sleep Initiation and Maintenance Disorders\|Sleep Deprivation	March 2016	Not Applicable
NCT05023993	City of Hope Medical Center\|National Cancer Institute (NCI)	Hematopoietic and Lymphoid Cell Neoplasm\|Malignant Solid Neoplasm\|Prediabetes	June 23, 2022	Not Applicable
NCT04614714	University of California, Davis	Preterm Birth\|Inadequate Milk Production	January 2023	Phase 2\|Phase 3
NCT03635411	Elysium Health\|University of Pennsylvania	Recovery of Function	December 6, 2018	Phase 1
NCT03642990	Donna Hammond, PhD\|National Cancer Institute (NCI)\|ChromaDex, Inc.\|University of Iowa	Chemotherapy-induced Peripheral Neuropathy\|Breast Cancer Metastatic\|Platinum-resistant Recurrent Ovarian Cancer	November 8, 2019	Phase 2
NCT02835664	Maastricht University Medical Center\|Dutch Heart Foundation	Obesity\|Insulin Resistance	December 2016	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 409.43 mM ; Need ultrasonic)

H ₂ O : ≥ 50 mg/mL ( 409.43 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	8.1887 mL	40.9433 mL	81.8867 mL
5 mM	1.6377 mL	8.1887 mL	16.3773 mL
10 mM	0.8189 mL	4.0943 mL	8.1887 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (818.87 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (20.47 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (20.47 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (20.47 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] [1] Francesca Scatozza, et al. Nicotinamide inhibits melanoma in vitro and in vivo. J Exp Clin Cancer Res. 2020 Oct 7;39(1):211.

Synonyms

3-Pyridinecarboxamide

Nicotinamide

Aminicotin

Benicot

Delonin Amide

Dipegyl

NAM

Niacinamide

Nicamindon

Nicofort

Nicotilamide

Nicotine acid amide

Nicotinic acid amide

Nicotinic amide

Nicotylamide

Niocinamide

Niozymin

Pelonin amide

3-Pyridinecarboxylic acid amide

Vi-Nicotyl

Vitamin B₃ (niacinamide)

Vitamin B

Nicosan 2

3-Carbamoylpyridine

Pelmine

β-Pyridinecarboxamide

Nicobion

Nicosylamide

Nicovit

Niavit PP

Nicovitina

Nicamina

Nicasir

3-(Aminocarbonyl)pyridine

m-(Aminocarbonyl)pyridine

3-Amidopyridine

Papulex

Nictoamide

Pelmin

NSC 13128

NSC 27452

Vitamin B₃ (nicotinamide)